2023
DOI: 10.3390/vaccines12010014
|View full text |Cite
|
Sign up to set email alerts
|

Evaluating Influenza Vaccination Practices among COPD Patients

Walid Al-Qerem,
Anan Jarab,
Judith Eberhardt
et al.

Abstract: Chronic Obstructive Pulmonary Disease (COPD) stands as a global health concern linked to considerable morbidity and mortality. In Jordan, the prevalence of COPD is substantial, but research in this area is limited. Exacerbations of COPD can lead to severe outcomes, including hospitalization and increased cardiovascular risk. Influenza is a significant trigger of exacerbations in COPD patients, and vaccination is recommended. However, studies have shown negative attitudes towards the influenza vaccine. This cro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 29 publications
1
0
0
Order By: Relevance
“…These findings are of extreme concern and are significantly lower than the values of 77% for seasonal influenza among Irish patients receiving immunoglobulin replacement therapy [ 25 ] and of 41% for pneumococcal vaccination among patients with chronic conditions in France [ 26 ]. Similar values of uptake have been observed for pneumococcal and influenza vaccinations with only 13.9% and 1.5% among patients with inflammatory arthritis in Bulgaria [ 27 ], 7.8% of diabetic patients in China [ 28 ], and 7% of chronic obstructive pulmonary disease patients who have received the influenza vaccine in Saudi Arabia [ 29 ]; in China, 3.29% and 6.69% of chronic disease patients aged < 65 years and ≥65 years have received the pneumococcal vaccine [ 30 ]. The multinomial logistic regression analysis showed that a higher number of comorbidities increased the likelihood of having received vaccinations, as confirmed in other studies [ 31 , 32 ].…”
Section: Discussionsupporting
confidence: 64%
“…These findings are of extreme concern and are significantly lower than the values of 77% for seasonal influenza among Irish patients receiving immunoglobulin replacement therapy [ 25 ] and of 41% for pneumococcal vaccination among patients with chronic conditions in France [ 26 ]. Similar values of uptake have been observed for pneumococcal and influenza vaccinations with only 13.9% and 1.5% among patients with inflammatory arthritis in Bulgaria [ 27 ], 7.8% of diabetic patients in China [ 28 ], and 7% of chronic obstructive pulmonary disease patients who have received the influenza vaccine in Saudi Arabia [ 29 ]; in China, 3.29% and 6.69% of chronic disease patients aged < 65 years and ≥65 years have received the pneumococcal vaccine [ 30 ]. The multinomial logistic regression analysis showed that a higher number of comorbidities increased the likelihood of having received vaccinations, as confirmed in other studies [ 31 , 32 ].…”
Section: Discussionsupporting
confidence: 64%